Skip to content
ClinCalc Pro
Menu
Dihydropyridine calcium-channel blocker

Lercanidipine hydrochloride

Brand names: Zanidip

Lercanidipine is a dihydropyridine calcium-channel blocker used in the treatment of essential hypertension.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits L-type calcium channels in vascular smooth muscle, producing arterial vasodilatation that lowers peripheral vascular resistance and blood pressure.

Prescribing in practice

  • Vasodilatory adverse effects such as ankle oedema, flushing and headache are common and may be dose-limiting.
  • It is contraindicated in significant hepatic or severe renal impairment, in unstable angina, in untreated heart failure and within a short period after myocardial infarction, and grapefruit juice should be avoided as it increases drug exposure.
  • It is best taken before food, as taking it with a high-fat meal can substantially increase absorption.

Monitoring

Monitor blood pressure for response and review the patient for ankle oedema and other vasodilatory effects.

Counselling the patient

  • Take the medicine before food and avoid grapefruit juice.
  • Ankle swelling, flushing or headache may occur, especially when starting treatment.
  • Keep taking it regularly, as it controls rather than cures high blood pressure.

Evidence & guidelines

Dihydropyridine calcium-channel blockers such as lercanidipine are recommended for hypertension in NICE guidance, with well-established efficacy in lowering blood pressure.

Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.